ROCKVILLE, Md., Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type ...

and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age ...

(RTTNews) - REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II ...

The company is trading for roughly the cash on its balance sheet. The RGX-121 program is presently the furthest in development. REGENXBIO is pushing ahead with partner Nippon Shinyaku to ...

That partner, Japan’s Nippon Shinyaku, is handing over $110 million upfront to lead on the commercialization of two gene therapies—RGX-121 for Hunter syndrome and RGX-111 for Hurler syndrome.

Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie ...

“ABBV-RGX-314 has the potential to help millions of people living with wet AMD and DR, globally, who are facing these debilitating diseases,” said Curran Simpson, president and chief executive officer ...

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization ...

In return for its investment, Nippon Shinyaku will gain access to two of Regenxbio’s gene therapies. The most mature of the assets is RGX-121, which is being tested for mucopolysaccharidosis type II, ...

RGX-202 is under clinical development by RegenxBio and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData, Phase II drugs for Duchenne Muscular Dystrophy have a 61% phase ...